 |
 |
I love this sentence; 'The multi-center, 60-subject Phase 2b study in individuals with Parkinson's disease is a double-blind, placebo-controlled, four-way crossover, dose range finding, clinical trial designed to evaluate dose response effect of repeated eltoprazine dosing on safety, tolerability and dyskinesia severity using state-of-the-art rating scales, diaries and motion sensors (ClinicalTrials.gov Identifier: NCT02439125).' ;-)) Nic 63/21 On 6 June 2015 at 05:29, Rayilyn Brown <[log in to unmask]> wrote: > http://money.cnn.com/news/newsfeeds/articles/globenewswire/10137013.htm > Ray > Rayilyn Brown > Past Director AZNPF > Arizona Chapter National Parkinson Foundation > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto: > [log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn